President & CEO @AcadForPatients, former Editor @BioCentury. Preparing patients to contribute their expertise to drug development, regulation, access. She/her.
Joined September 2015
- Tweets1.7K
- Following905
- Followers1.3K
- Likes1.2K
Susan Schaeffer retweeted
barbie’s wheelchair vs my actual wheelchair: a critical comparison
aka the best twitter thread i will ever post
strap in
#Barbie
ALT a barbie doll with light skin and blonde hair sitting in her barbie wheelchair which is a pink manual wheelchair.
ALT katie, a white woman with blondish hair, sitting in her pink manual wheelchair in the exact same pose as the barbie in the previous photo.
Susan Schaeffer retweeted
“If courts can overturn drug approvals without regard for science or evidence,” the letter said, “or for the complexity required to fully vet the safety and efficacy of new drugs, any medicine is at risk for the same outcome as mifepristone.”
Breaking News: Executives from over 250 drug companies called for the reversal of a judge’s abortion drug ruling, warning it could disrupt the entire industry. nyti.ms/41ilSJW
Susan Schaeffer retweeted
Very cool that @GeneDx will send a notification about a relevant clinical trial to all people who received a genetic diagnosis for said disease.
Susan Schaeffer retweeted
This #GivingTuesday help @AcadForPatients empower patients to advocate for research that centers on their needs and preferences. Go to patients-academy.org/donate #empoweredpatients #powerful #donate
Susan Schaeffer retweeted
We had a bad day. Our staff, these folks, and many others kept everyone safe. We thank them and you all.
Susan Schaeffer retweeted
This 🧵captures the spirit of @theNASEM's new #ResearchEquity report perfectly. I have hope we can turn things around bc of the leadership of folks like @KBibbinsDomingo, @ahelman99, my other committee members & the MANY more doing the work unseen in the trenches.
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Susan Schaeffer retweeted
Great thread on the importance of engaging patient communities in the development of PROs that are relevant and sensitive
Short 🧵on symptom measurement in #LongCovid / #MECFS and other chronic illnesses. We need to do better. Many of the symptoms that we're trying to track don't have a physical biomarker, and while patient-reported outcomes (PROs) are helpful, then need to be far more (1/n)
Susan Schaeffer retweeted
This #GivingTuesday you can help us help patients advocate for research that meets their needs. And if you donate on Facebook, your donation could go twice as far with matching funds! facebook.com/donate/32263310…
Susan Schaeffer retweeted
Very excited to have such awesome panelists talk Korean biotech -- a relatively untapped source of innovation for partnerships
16/ Did you know #ChinaSummit21 has large delegation of Korea biotech C-Suite? This year @BioCentury & @bio_korea have organized a panel chaired by @jeff_cranmer + Korea Biotech Roadshow Track w/KHIDI to explore cross-border opportunities. Register here: conferences.biocentury.com/c…
Susan Schaeffer retweeted
Join us Monday! "Overcoming Barriers to Diversifying Clinical Trials"
Discussing role of
-Journals: Robert Golub @JAMA_current & Eric Rubin @NEJM
-@CMSGov Dora Hughes & LaShawn McIver
-IRBs: Jerry Menikoff @HHSGov & Ann Meeker-O’Connell @US_FDA
nationalacademies.org/event/…
Susan Schaeffer retweeted
Proud of the journey we have been on @AlexionPharma. Saying goodbye today doesn’t mean that I won’t be a champion for people with rare disease and my Alexion colleagues in the future. Onward!
Today we announced the completion of AstraZeneca’s acquisition of @AlexionPharma. This new group is now known as Alexion, AstraZeneca Rare Disease and headquartered in Boston, US. know.az/36Q1tBV
Susan Schaeffer retweeted
IMPORTANT: “FDA does not consider reimbursement for travel expenses to & from the #clinicaltrials site & assoc costs, eg airfare, parking, & lodging to raise issues reg undue influence.”
📣 Sponsors of trials can pay for this. Participants, ask! #advocacy
bit.ly/3eSDmXY
This Post is from an account that no longer exists. Learn more
Susan Schaeffer retweeted
I felt the same way when I got my first dose as well. Get my second dose of Pfizer on April 10th.
Susan Schaeffer retweeted
How could we expedite the vaccine development process to create life-saving tools in 100 days? 🤔
@BioCentury explores, with comments from CEPI Board Member and Head of @TakedaPharma vaccines @rvenkayya and @JanssenGlobal's @mmammen ⏬
biocentury.com/article/63522…
Susan Schaeffer retweeted
In recognition of rare disease day, I am excited to share what I have been working on with my awesome colleagues @AlexionPharma.
ir.alexion.com/news-releases…
Susan Schaeffer retweeted
Whew! My blood was boiling this afternoon. Thanks for all the support, Internet friends.
Susan Schaeffer retweeted
ICYMI: Patients' Academy CEO @BiotechSusan recently spoke with eyeforpharma on why patient education is key to scaling engagement and increasing participation in research.
social.eyeforpharma.com/pati…